2021 –
Leitende Ärztin, Hämatologie, Tumorzentrum, Claraspital Basel

2018 – 2020
Leitende Oberärztin, Rems-Murr-Klinikum Winnenden

Seit 2016
MDS Center of Excellence

2013 – 2018
Oberärztin mit Bereichsleitung Hämatologie, Leitung des Hämatologischen Speziallabors
Transfusionsverantwortliche, Rems-Murr-Klinikum Winnenden

2013
Erlangung der Zusatzbezeichnung «Hämostaseologie»

2011 – 2013
Funktionsoberärztin, Universitätsklinikum Carl-Gustav Carus Dresden

2011
Facharztprüfung Innere Medizin/Hämatologie/Onkologie

2008
Promotion: Dissertation “Role of NADPH-Oxidase in Thrombin-induced signal transduction of vascular smooth muscle cells“ am Institut für kardiovaskuläre Physiologie, Frankfurt/Main (Note: Magna cum laude)

2007 – 2011
Assistenzärztin, Universitätsklinikum Carl-Gustav Carus Dresden

6/2010-7/2010
Clinical Observer am King´s College Hospital London (Prof. Mufti)

2006 – 2007
Assistenzärztin im KKH Freiberg (Sachsen) (Schwerpunkt allgemeine Innere Medizin)

2005 – 2006
Assistenzärztin im Krankenhaus der “Humaine-Klinik” Dresden (Schwerpunkt
Onkologie/Palliativmedizin)

2004
Approbation, Frankfurt am Main

10/1997 – 12/2004
Studium der Medizin am Universitätsklinikum der Johann- Wolfgang-Goethe
Universität, Frankfurt am Main

• European Society of Hematology (EHA)
• European Society of Medical Oncology (ESMO)
• Deutsche Gesellschaft für Hämatologie und Onkologie
• (DGHO)
• Deutsche Gesellschaft für Innere Medizin (DGIM)
• International Society of Laboratory Hematology (ISLH)
• International Society of Thrombosis and Haemostasis (ISTH)
• Member of „World Federation of Hemophilia“ (WFH)
• American Society of Hematology (ASH)
• Gesellschaft für Thrombose und Hämostaseforschung (GTH)

• Hirsiger JR, Tzankov A, Alborelli I, Recher M, Daikeler T, Parmentier S, Berger CT: Case Report: mRNA vaccination-mediated STAT3 overactivation with agranulocytosis and clonal T-LGL expansion. Front Immunol: 14.
• Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH: Efficacy and safety of ruxolitinib in patients with newly diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Ann Hematol: 102 (2): 349–358.
• Middeke JM, Teipel R, Röllig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, Stölzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Study Alliance Leukemia (SAL).Leuk Lymphoma. 2021 Jun;62(6):1432-1440. doi: 10.1080/10428194.2020.1864354. Epub 2021 Jan 5.PMID: 33399480
• Judith Gecht, Ioannis Tsoukakis, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Martin Griesshammer, Holger Schulz, Wiebke Hollburg, Joachim R. Göthert, Katja Sockel, Florian H. Heidel, Norbert Gattermann, Christoph Maintz, Haifa K. Al-Ali, Uwe Platzbecker, Richard Hansen, Mathias Hänel, Stefani Parmentier, Martin Bommer, Heike L. Pahl, Fabian Lang, Martin Kirschner, Susanne Isfort, Tim H. Brümmendorf, Konstanze Döhner and Steffen Koschmieder. Kidney Dysfunction Is Associated with Thrombosis and Disease Severity inMyeloproliferative Neoplasms: Implications from the German Study Group forMPN Bioregistry. 2021 Aug 13;13(16):4086
• Martin Kirschner, Nicole do Ó Hartmann, Stefani Parmentier, Christina Hart, Larissa Henze, Guido Bisping, Martin Griesshammer, Florian Langer, Ingrid Pabinger-Fasching, Axel Matzdorff, Hanno Riess and Steffen Koschmieder. Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). Cancers 2021, 13, 2905.
• Parmentier S, Kramer M, Weller S, Schuler U, Ordemann R, Rall G, Schaich M, Bornhäuser M, Ehninger G, Kroschinsky F. Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors. Ann Hematol. 2020 Sep 15. Online ahead of print.
• Stölzel F, Lüer T, Löck S, Parmentier S, Kuithan F, Kramer M, Alakel NS, Sockel K, Taube F, Middek JM, Schetelig J, Röllig C, Paulus T, Kotzerke J, Ehninger G, Bornhäuser M, Schaich M, Zöphel K. The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial. Haematologica. 2019 Aug 29.
• Stratmann J, van Kann E, Rummelt C, Koschade S, Röllig C, Lübbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, Becker von Rose A, Ballo O, Steffen B, Serve H, Brandts C, Shaid S. Leuk Res. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. 2019 Oct; 85:106192.
• Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial. Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497.
• Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL). Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. Ann Hematol. 2016 Sep;95(9):1399-410.
• Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016 Mar 5; 9:18.
• Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, Bergmann F, Schilling K, Brümmendorf TH, Petrides PE, Tiede A, Matzdorff A, Griesshammer M, Riess H, Koschmieder S. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016 Apr;95(5):707-18. Review.
• Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Study Alliance Leukaemia. 6 Lancet Oncol. 2015 Dec;16(16):1691-9.
• von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhäuser M, von Bonin M. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. Stem Cells. 2016 Feb;34(2):357-66.
• Matzdorff A, Riess H, Bergmann F, Bisping G, Koschmieder S, Parmentier S, Petrides PE, Sosada M. Cancer Screening in Patients with Idiopathic Venous Thromboembolism--a Position Paper of the German Society of Hematology and Oncology Working Group on Hemostasis. Oncol Res Treat. 2015;38(9):454-8. Review.
• Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7.
• Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, Griese EU. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol. 2015 Oct;171(1):145-8.
• Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Study Alliance Leukemia. Leukemia. 2015 May;29(5):1060-8.
• Oelschlaegel U, Westers TM, Mohr B, Kramer M, Parmentier S, Sockel K, Thiede C, Bornhäuser M, Ehninger G, van de Loosdrecht AA, Platzbecker U. Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring. Haematologica. 2015 Mar;100(3):e93-6.
• Parmentier S, Richter S. Bone marrow metastases by alveolar rhabdomyosarcoma in a 31-year-old patient.  Blood. 2013 Sep 19;122(12):2000. No abstract available.
• Middeke JM, Bruck N, Parmentier S, Bornhäuser M, Schetelig J. Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome. Ann Hematol. 2014 Mar;93(3):531-2.
• Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi: 10.1200/JCO.2012.46.4743. Epub 2013 Apr 29.
• Oelschlaegel U, Parmentier S, Platzbecker U. Comment to the response to "severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome". Ann Hematol. 2013 Apr;92(4):575-6. doi: 10.1007/s00277-012-1570-7. Epub 2012 Sep 9.
• Parmentier S, Meinel J, Oelschlaegel U, Mohr B, Ehninger G, Schaich M, Platzbecker U. Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome. Ann Hematol. 2012 Dec;91(12):1979-81. doi: 10.1007/s00277-012-1488-0. Epub 2012 May 11.
• Parmentier S, Radke J.; Pseudo-Auer rods in a patient with newly diagnosed IgG myeloma. Blood. 2012 Jan 19;119(3):650. No abstract available.
• Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U, Ordemann R, Rall G, Schaich M, Bornhäuser M, Ehninger G, Kroschinsky F. Haematologica. 2012 May;97(5):723-30. doi: 10.3324/haematol.2011.056879. Epub 2011 Dec 16.
• Oelschlaegel U, Mohr B, Schaich M, Kroschinsky F, Parmentier S, Bornhäuser M, Ehninger G, Thiede C. Leukemia. Reply to: 'Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity' by Kern et al. 2011 May;25(5):895-7. doi: 10.1038/leu.2011.23. Epub 2011 Feb 18.
• List C, Parmentier S, Jahn S, Schuler U, Kroschinsky F. Internist (Berl). [Bone marrow carcinosis as initial presentation of adenocarcinoma]. 2011 Mar;52(3):324-7. doi: 10.1007/s00108-010-2657-7. German.
• 8 Brandes RP, Beer S, Ha T, Busse R.; Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1794-800. Epub 2003 Aug 21.
• Brandes RP, Miller FJ, Beer S, Haendeler J, Hoffmann J, Ha T, Holland SM, Görlach A, Busse R.; The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic Biol Med. 2002 Jun 1;32(11):1116-22.
• Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, Görlach A.; Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb Haemost. 2001 Jun;85(6):1104-10.
• Isolation of Mouse Cardiac Microvascular Endothelial Cells
  Brandes RP, Beer S; In book: Methods in Endothelial Cell Biology (pp.15-22); January 2004